Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/his.12437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
Cancer
April 2024
Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Article Synopsis
- * Researchers evaluated the infiltration levels of TLSs and TB through various staining methods and developed a nomogram model to analyze survival data.
- * The findings revealed that a higher TLS/TB ratio correlated with better overall and relapse-free survival, and the new TLS-TB profile outperformed traditional methods in predicting patient outcomes.
Comprehensive study of clinicopathological and immune cell infiltration and lactate dehydrogenase expression in patients with thymic epithelial tumours.
Int Immunopharmacol
January 2024
Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310000, Zhejiang, China; Thoracic Oncology Laboratory, Jiangxi Cancer Hospital, Nanchang 330006, Jiangxi, China; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), Hangzhou 310000, Zhejiang, China. Electronic address:
Background: Lactate dehydrogenase (LDH) has emerged as a promising biomarker for cancer. However, the current understanding of LDH and circulating LDH expression in thymic epithelial tumour (TET) is lacking.
Methods: A comprehensive literature review and meta-analysis were performed to evaluate the clinical significance of circulating LDH levels in patients with TET.
Immunohistochemical study of the expressed cluster differentiation markers proteins type 20 and 56 in breast tissues from a group of Iraqi patients with breast cancers.
Asian Pac J Cancer Prev
October 2023
Clinical Communicable Diseases Research unit, College of Medicine, University of Baghdad, Iraq.
Background: Tumor-infiltrating lymphocytes (TIL) are important immunological components in response to cancers. Patients with higher numbers of TIL in breast cancerous tissues, comprising T- cytotoxic and T - helper cells along with B- and rare natural killer (NK) cells, have more favorable clinical outcomes.
Objective: To analyze the rate of the expressed surface biomarker proteins of CD20-B cells and CD56- NK cells on the infiltrative lymphocytic subpopulations in a group of breast tumorous tissues (invasive and benign) from female patients in Iraq and explore the relations to the grade of the invasive breast cancerous tissues.
How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study.
Risk Manag Healthc Policy
September 2023
Department of Pharmacy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Background: Cancer is a significant health concern and is China's leading cause of mortality. Targeted therapies, such as trastuzumab and rituximab, have enhanced clinical treatment efficacy. However, their high costs burden patients and healthcare systems considerably.
View Article and Find Full Text PDFCure of Disseminated Human Lymphoma with [Ac]Ac-Ofatumumab in a Preclinical Model.
J Nucl Med
June 2023
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
Immunotherapies that target the CD20 protein expressed on most non-Hodgkin lymphoma cells have improved clinical outcomes, but relapse is common. We prepared Ac-labeled anti-CD20 ofatumumab and evaluated its in vitro characteristics and therapeutic efficacy in a murine model of disseminated human lymphoma. Ac was chelated by DOTA-ofatumumab, and radiochemical yield, purity, immunoreactivity, stability, and chelate number were determined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!